In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...

One month after Integra LifeSciences recalled its wound and burn devices amid safety concerns, the medtech company is cutting ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...

Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...